

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **GAL RABBIT PAB**

货号: \$221341 产品全名: GAL 兔多抗

基因符号 GALN; GLNN; GMAP; GAL-GMAP

UNIPROT ID: P22466 (Gene Accession - NP\_057057)

背景: This gene encodes a neuroendocrine peptide that is widely expressed in the central and peripheral nervous systems and also the gastrointestinal tract, pancreas, adrenal gland and urogenital tract. The encoded protein is a precursor that is proteolytically processed to generate two mature peptides: galanin and galanin message-associated peptide (GMAP). Galanin has diverse physiological functions including nociception, feeding and energy homeostasis, osmotic regulation and water balance. GMAP has been demonstrated to possess antifungal activity and hypothesized to be part of the innate immune system.

抗原: Synthetic peptide of human GAL

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 5000-10000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Neuroscience, Cardiovascular


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human cervical cancer tissue using 221341(GAL Antibody) at a dilution of 1/20(Secreted).



In comparision with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with the synthetic peptide and then with 221341(Anti-GAL Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human tonsil tissue using 221341(Anti-GAL Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human tonsil tissue is first treated with synthetic peptide and then with D262891(Anti-GAL Antibody) at dilution 1/20.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010